



FREQUENTLY ASKED QUESTIONS FOR PATIENTS

When will your Phase 2a clinical trials begin?

We expect to begin enrolling patients in our upcoming eating disorder trial in 4Q 2021 and in our fibromyalgia trial in the first half of 2022.

How can I participate in one of your upcoming clinical trials?

Until our Principal Investigators begin enrolling patients, you can sign up on the Patients portion of our website at tryptherapeutics.com/patients to be contacted once enrollment begins for the respective studies. Our Phase 2a clinical trials are fairly limited since we are primarily seeking to evaluate the effect size of our treatments for patients rather than optimizing the treatment regimen; our Phase 2a study for eating disorders is expected to enroll a total of 10 patients, and our Phase 2a study for fibromyalgia is expected to enroll 20 patients.

Where will the clinical trials be conducted?

Our Phase 2a study for eating disorders will be conducted at the University of Florida in Gainesville, Florida. Our Phase 2a study for fibromyalgia will be conducted at the University of Michigan in Ann Arbor, Michigan.

When will your products be available for patients?

Before our proprietary drug product, TRP-8803, can be commercialized, we expect that we will need to complete Phase 2a, Phase 2b, and Phase 3 clinical trials. We would then file a New Drug Application with the FDA to seek approval to market the new product. The review by the FDA often takes at least 12 months. Because of those important and stringent

requirements for new drug products, then it will be at least a few years before physicians will be able to prescribe our products to patients.

How often would I need to be treated with your products for them to be effective?

We expect that the research we are conducting with our upcoming clinical trials will help determine how often patients would need to be treated with our psilocybin-based products. Our Phase 2a studies will evaluate both single-dose and dual-dose treatments, all with accompanying psychotherapy.